Since Ido-1 expression in cancer is modulated by interaction with stromal and immune cells, we extended our analysis to tumor samples interrogating the clinical dataset of TCGA NSCLC cohort [3]. This evidence concerns the gene IDO1 and non-small cell lung carcinoma.